Cargando…

P02-10. Plant expression of chimeric Gag/gp41 virus-like particles as a mucosally-targeted subunit vaccine against HIV-1

Detalles Bibliográficos
Autores principales:	Kessans, SA, Frater, J, Matoba, N, Mor, T
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767637/ http://dx.doi.org/10.1186/1742-4690-6-S3-P15

Ejemplares similares

P12-16. Biochemical and immunological characterization of the plant-derived candidate HIV-1 mucosal vaccine CTB-MPR
por: Matoba, N, et al.
Publicado: (2009)

Biological and biochemical characterization of HIV-1 Gag/dgp41 virus-like particles expressed in Nicotiana benthamiana
por: Kessans, Sarah A, et al.
Publicado: (2013)

Immunological Characterization of Plant-Based HIV-1 Gag/Dgp41 Virus-Like Particles
por: Kessans, Sarah A., et al.
Publicado: (2016)

P19-02. High protection of female macaques from repeated intravaginal challenges with SHIV-162P3 upon mucosal vaccination with Gp41 subunits-virosomes
por: Bomsel, M, et al.
Publicado: (2009)

Virus-like particles highly expressing DC-SIGN concentrate trimeric HIV-envelope proteins with noncovalently linked immunoreactive gp120 and gp41
por: Vyas, GN
Publicado: (2012)

A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles
por: Meador, Lydia R., et al.
Publicado: (2017)

Dynamics and frequency of Gag transmitted polymorphisms in Zambia
por: Schaefer, M, et al.
Publicado: (2012)

Characterization and quantitation of fluorescent Gag virus-like particles
por: Gutiérrez-Granados, Sonia, et al.
Publicado: (2013)

Mucosal Vaccines from Plant Biotechnology
por: Mason, Hugh S., et al.
Publicado: (2015)

P12-14. Design of hydrophilic, helical peptides that mimic the 4E10 epitope of HIV-1 gp41
por: Lorenz, IC, et al.
Publicado: (2009)

Assessing the protective efficacy of antibodies to the HIV gp41 region by active vaccination
por: Sharma, SK, et al.
Publicado: (2012)

P10-10. HIV-1 Gag virus like particles pseudotyped with CD40 ligand to stimulate innate immune responses
por: Köstler, J, et al.
Publicado: (2009)

Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors
por: Manasa, Justen, et al.
Publicado: (2017)

Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2012)

Analysis of gp41 epitopes in model viral membranes to study HIV-1 neutralization
por: Reichart, T, et al.
Publicado: (2012)

P10-09. Altered release of RANTES from human, normal platelets: contribution of distinct HIV-1MN gp41 peptides
por: Cognasse, F, et al.
Publicado: (2009)

P05-13. Fragments of HIV-1 gp41 derivatives presented on virus-like particles with preserved binding affinity for broadly neutralizing antibodies
por: Benen, T, et al.
Publicado: (2009)

P02.41. Yoga for musculoskeletal conditions: a systematic review of intervention protocols
por: Ward, L, et al.
Publicado: (2012)

Soluble and bacteriophage T4 displayed gp41 mutant proteins as HIV-1 vaccine candidates
por: Gao, G, et al.
Publicado: (2012)

Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans
por: Katinger, D, et al.
Publicado: (2012)

P11-20. HIV-1 gp41-specific mucosal IgAs from highly exposed but IgG seronegative women block HIV-1 epithelial transcytosis and neutralize CD4+ cell infection
por: Tudor, D, et al.
Publicado: (2009)

Immunisation with the membrane proximal external region of gp41 of HIV-1 grafted into the transmembrane envelope protein of a gammaretrovirus
por: Strasz, N, et al.
Publicado: (2012)

P09-13. Structure of HIV-1 gp41 interactive region: layered architecture and basis of conformational mobility
por: Pancera, M, et al.
Publicado: (2009)

Early presentation of HIV-1 KF11Gag and KK10Gag protective epitopes facilitate rapid CD8+ T cell activation and killing of virus infected cells
por: Kløverpris, HN, et al.
Publicado: (2012)

P05-04. Neutralizing antibodies induced by immunization with liposomal gp41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes
por: Matyas, GR, et al.
Publicado: (2009)

DNA vaccines that express the MPER of HIV-1 gp41 elicit different antibodies depending upon their transmembrane and cytoplasmic domains
por: Scott, JK, et al.
Publicado: (2012)

Anti-gp41 antibodies inhibit infection and transcytosis of HIV-1 infectious molecular clones expressing transmitted/founder envelopes
por: Jain, S, et al.
Publicado: (2012)

A gp41 MPER-specific llama VHH requires a hydrophobic CDR3 determinant for neutralization but not for antigen recognition
por: Weissenhorn, W, et al.
Publicado: (2012)

P04-06. Evolution of an anti-MPER gp41 antibody response that mediates broad HIV-1 cross-neutralization
por: Gray, E, et al.
Publicado: (2009)

Characterisation of a spumavirus Gag protein
por: Goldstone, David C, et al.
Publicado: (2013)

Deep sequencing reveals an association between HIV-1 subtype C mutations in gp41 MPER epitopes and mother-to-child transmission
por: Yin, L, et al.
Publicado: (2012)

P03-02. SCID-hu mice generate HIV specific human immune responses after gp96 vaccination
por: Gonzalez, LE, et al.
Publicado: (2009)

P12-04. Topology of the C-terminal tail of HIV-1 gp41: Differential exposure of the Kennedy epitope on cell and viral membranes
por: Steckbeck, JD, et al.
Publicado: (2009)

P12-08. Membrane-specific antibodies that simultaneously bind to gp41 of HIV-1 and membrane lipid epitopes are induced by immunization with liposomes
por: Beck, Z, et al.
Publicado: (2009)

A prime-boost immunization with rBCG expressing HIV-1 Gag, RT and gp120 and SAAVI MVA-C elicits immune responses in blood and MALT of rhesus macaques
por: Chege, GK, et al.
Publicado: (2012)

Selection analyses of paired HIV-1 gag and gp41 sequences obtained before and after antiretroviral therapy
por: Tzou, Philip L., et al.
Publicado: (2018)

Development of chimeric HIV Env immunogens for mucosal delivery with attenuated canine distemper virus (CDV) vaccine vectors
por: Zhang, X, et al.
Publicado: (2012)

454 pyrosequencing and bioinformatics analysis of the lineage of the broad and potent gp41-directed antibody 10e8
por: Ofek, G, et al.
Publicado: (2012)

Post-transcriptional control of HIV-1 Gag expression
por: Phalora, Prabhjeet, et al.
Publicado: (2013)

P11-15. Induction of a mucosal immune response to HIV after systemic immunization with poly(lactic acid) nanoparticles formulated with gag antigen and polyI:C
por: Primard, C, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_ctrh2aafogph3rkjeh196hpd0v